Michael Rullmann

Dr. Michael Rullmann

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2009 in NeuroImage
Verified
Journal Article
Closed access
MRMichael Rullmann
Michael Rullmann
AAAlfred Anwander
Alfred Anwander
MDM Dannhauer
M Dannhauer
SWS Warfield
S Warfield
FDF Duffy
F Duffy
Carsten WoltersCarsten Wolters
Carsten Wolters

14 February 2017 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
SKSimon Kaller
Simon Kaller
MRMichael Rullmann
Michael Rullmann
MPMarianne Patt
Marianne Patt
GBGeorg-Alexander Becker
Georg-Alexander Becker
JLJulia Luthardt
Julia Luthardt
OSOsama Sabri
Osama Sabri

1 February 2017 in Cell Metabolism
Verified
Journal Article
Closed access
Mohammed HankirMohammed Hankir
Mohammed Hankir
FSFlorian Seyfried
Florian Seyfried
CHConstantin A. Hintschich
Constantin A. Hintschich
TDThi-Ai Diep
Thi-Ai Diep
KKKaren Kleberg
Karen Kleberg
WFWiebke K. Fenske
Wiebke K. Fenske

9 January 2017 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
SHSwen Hesse
Swen Hesse
GBGeorg-Alexander Becker
Georg-Alexander Becker
MRMichael Rullmann
Michael Rullmann
ABAnke Bresch
Anke Bresch
JLJulia Luthardt
Julia Luthardt
OSOsama Sabri
Osama Sabri

17 April 2018 in Brain
Verified
Journal Article
Open access
PDF file
OSOsama Sabri
Osama Sabri
PMPhilipp M Meyer
Philipp M Meyer
SGSusanne Gräf
Susanne Gräf
SHSwen Hesse
Swen Hesse
SWStephan Wilke
Stephan Wilke
PBPeter Brust
Peter Brust
In early Alzheimer’s dementia, there is a need for PET biomarkers of disease progression with close associations to cognitive dysfunction that may aid to predict further cognitive decline and neurodegeneration. Amyloid biomarkers are not suitable for that purpose. The α4β2 nicotinic acetylcholine receptors (α4β2-nAChRs) are widely abundant in the human brain. As neuromodulators they play an important role in cognitive functions such as attention, learning and memory. Post-mortem studies reported lower expression of α4β2-nAChRs in more advanced Alzheimer’s dementia. However, there is ongoing controversy whether α4β2-nAChRs are reduced in early Alzheimer’s dementia. Therefore, using the recently developed α4β2-nAChR-specific radioligand (−)-18F-flubatine and PET, we aimed to quantify the α4β2-nAChR availability and its relationship to specific cognitive dysfunction in mild Alzheimer’s dementia. Fourteen non-smoking patients with mild Alzheimer’s dementia, drug-naïve for cholinesterase therapy, were compared with 15 non-smoking healthy controls matched for age, sex and education by applying (−)-18F-flubatine PET together with a neuropsychological test battery. The one-tissue compartment model and Logan plot method with arterial input function were used for kinetic analysis to obtain the total distribution volume (VT) as the primary, and the specific binding part of the distribution volume (VS) as the secondary quantitative outcome measure of α4β2-nAChR availability. VS was determined by using a pseudo-reference region. Correlations between VT within relevant brain regions and Z-scores of five cognitive functions (episodic memory, executive function/working memory, attention, language, visuospatial function) were calculated. VT (and VS) were applied for between-group comparisons. Volume of interest and statistical parametric mapping analyses were carried out. Analyses revealed that in patients with mild Alzheimer’s dementia compared to healthy controls, there was significantly lower VT, especially within the hippocampus, fronto-temporal cortices, and basal forebrain, which was similar to comparisons of VS. VT decline in Alzheimer’s dementia was associated with distinct domains of impaired cognitive functioning, especially episodic memory and executive function/working memory. Using (−)-18F-flubatine PET in patients with mild Alzheimer’s dementia, we show for the first time a cholinergic α4β2-nAChR deficiency mainly present within the basal forebrain-cortical and septohippocampal cholinergic projections and a relationship between lower α4β2-nAChR availability and impairment of distinct cognitive domains, notably episodic memory and executive function/working memory. This shows the potential of (−)-18F-flubatine as PET biomarker of cholinergic α4β2-nAChR dysfunction and specific cognitive decline. Thus, if validated by longitudinal PET studies, (−)-18F-flubatine might become a PET biomarker of progression of neurodegeneration in Alzheimer’s dementia.

5 November 2015 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
MRMichael Rullmann
Michael Rullmann
JDJuergen Dukart
Juergen Dukart
KHKarl-Titus Hoffmann
Karl-Titus Hoffmann
JLJulia Luthardt
Julia Luthardt
STSolveig Tiepolt
Solveig Tiepolt
HBHenryk Barthel
Henryk Barthel
Neocortical atrophy reduces PET signal intensity, potentially affecting the diagnostic efficacy of β-amyloid (Aβ) brain PET imaging. This study investigated whether partial-volume effect correction (PVEC), adjusting for this atrophy bias, improves the accuracy of 18F-florbetaben Aβ PET. Methods: We analyzed 18F-florbetaben PET and MRI data obtained from 3 cohorts. The first was 10 patients with probable Alzheimer disease (AD) and 10 age-matched healthy controls (HCs), the second was 31 subjects who underwent in vivo imaging and postmortem histopathology for Aβ plaques, and the third was 5 subjects who underwent PET and MRI at baseline and 1 y later. The imaging data were coregistered and segmented. PVEC was performed using the voxel-based modified Müller-Gärtner method (PVELab, SPM8). From the PET data, regional and composite SUV ratios (SUVRs) with and without PVEC were obtained. In the MRI data, mesial temporal lobe atrophy was determined by the Scheltens mesial temporal atrophy scale and gray matter volumes by voxel-based morphometry. Results: In cohort 1, PVEC increased the effect on AD-versus-HC discrimination from a Cohen d value of 1.68 to 2.0 for composite SUVRs and from 0.04 to 1.04 for mesial temporal cortex SUVRs. The PVEC-related increase in mesial temporal cortex SUVR correlated with the Scheltens score (r = 0.84, P < 0.001), and that of composite SUVR correlated with the composite gray matter volume (r = −0.75, P < 0.001). In cohort 2, PVEC increased the correlation coefficient between mesial temporal cortex SUVR and histopathology score for Aβ plaque load from 0.28 (P = 0.09) to 0.37 (P = 0.03). In cohort 3, PVEC did not affect the composite SUVR dynamics over time for the Aβ-negative subject. This finding was in contrast to the 4 Aβ-positive subjects, in 2 of whom PVEC changed the composite SUVR dynamics. Conclusion: The influence of PVEC on 18F-florbetaben PET data is associated with the degree of brain atrophy. Thus, PVEC increases the ability of 18F-florbetaben PET to discriminate between AD patients and HCs, to detect Aβ plaques in the atrophic mesial temporal cortex, and potentially to evaluate changes in brain Aβ load over time. As such, the use of PVEC should be considered for quantitative 18F-florbetaben PET scans, especially in assessing patients with brain atrophy.